Literature DB >> 12165093

Assessment of thymic output in common variable immunodeficiency patients by evaluation of T cell receptor excision circles.

V Guazzi1, F Aiuti, I Mezzaroma, F Mazzetta, G Andolfi, A Mortellaro, M Pierdominici, R Fantini, M Marziali, A Aiuti.   

Abstract

Common variable immunodeficiency (CVID) is a heterogeneous syndrome characterized by repeated infections and hypogammaglobulinaemia. Additionally, T-cell abnormalities including lymphopenia, decreased proliferation to mitogens and antigens, and the reduced production and expression of cytokines, have also been observed. In this study we have investigated the expression of naive, memory and activation markers in T-cell subpopulations in 17 CVID patients in comparison to age-matched normal controls. The numbers of CD4+ T cells, including CD45RA+CD62L+ and, to a lesser extent, CD45RA-CD62L+/RA+CD62L- were significantly reduced in patients, whereas CD8+ T cells were within normal range. In contrast, HLA-DR+ cells were increased both in CD4+ and CD8+ T cells. To assess the thymic output, we analysed the presence of T-cell receptor excision circles (TRECs) in CD4+ and CD8+ T cells by quantitative PCR. TRECs were decreased significantly in patients and the rate of TREC loss was higher with increasing age. TRECs correlated with naive CD4+ T cells, whereas there was an inverse relationship between TRECs and CD8+HLA-DR+ and CD8+CD45RA-CD62L+/RA+CD62L- T cells. Our results suggest the presence of a defect in the naive T cell compartment with origin at the thymic level in CVID, and indicate that TREC may be a useful marker to monitor thymic function in this primary immunodeficiency.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12165093      PMCID: PMC1906453          DOI: 10.1046/j.1365-2249.2002.01893.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  35 in total

1.  Essential role of the thymus to reconstitute naive (CD45RA+) T-helper cells after human allogeneic bone marrow transplantation.

Authors:  A Heitger; N Neu; H Kern; E R Panzer-Grümayer; H Greinix; D Nachbaur; D Niederwieser; F M Fink
Journal:  Blood       Date:  1997-07-15       Impact factor: 22.113

2.  L-selectin in patients with common variable immunodeficiency (CVID): a comparative study with normal individuals.

Authors:  J G Zhang; L Morgan; G P Spickett
Journal:  Clin Exp Immunol       Date:  1996-05       Impact factor: 4.330

3.  In vivo estimates of division and death rates of human T lymphocytes.

Authors:  A R Mclean; C A Michie
Journal:  Proc Natl Acad Sci U S A       Date:  1995-04-25       Impact factor: 11.205

4.  Developmental control point in induction of thymic cortex regulated by a subpopulation of prothymocytes.

Authors:  G A Holländer; B Wang; A Nichogiannopoulou; P P Platenburg; W van Ewijk; S J Burakoff; J C Gutierrez-Ramos; C Terhorst
Journal:  Nature       Date:  1995-01-26       Impact factor: 49.962

5.  Interleukin 10 and immune restoration in common variable immunodeficiency.

Authors:  S Zielen; P Bauscher; D Hofmann; S C Meuer
Journal:  Lancet       Date:  1993-09-18       Impact factor: 79.321

6.  Enhancement of thymopoiesis after bone marrow transplant by in vivo interleukin-7.

Authors:  E Bolotin; M Smogorzewska; S Smith; M Widmer; K Weinberg
Journal:  Blood       Date:  1996-09-01       Impact factor: 22.113

7.  Intracellular cytokine production by human CD4+ and CD8+ T cells from normal and immunodeficient donors using directly conjugated anti-cytokine antibodies and three-colour flow cytometry.

Authors:  M E North; K Ivory; M Funauchi; A D Webster; A C Lane; J Farrant
Journal:  Clin Exp Immunol       Date:  1996-09       Impact factor: 4.330

8.  Study of B and T cell phenotypes in blood from patients with common variable immunodeficiency (CVID).

Authors:  J Farrant; G Spickett; N Matamoros; D Copas; M Hernandez; M North; H Chapel; A D Webster
Journal:  Immunodeficiency       Date:  1994

9.  Defects in antigen-driven lymphocyte responses in common variable immunodeficiency (CVID) are due to a reduction in the number of antigen-specific CD4+ T cells.

Authors:  M Funauchi; J Farrant; C Moreno; A D Webster
Journal:  Clin Exp Immunol       Date:  1995-07       Impact factor: 4.330

10.  Turnover of naive- and memory-phenotype T cells.

Authors:  D F Tough; J Sprent
Journal:  J Exp Med       Date:  1994-04-01       Impact factor: 14.307

View more
  22 in total

1.  International Consensus Document (ICON): Common Variable Immunodeficiency Disorders.

Authors:  Francisco A Bonilla; Isil Barlan; Helen Chapel; Beatriz T Costa-Carvalho; Charlotte Cunningham-Rundles; M Teresa de la Morena; Francisco J Espinosa-Rosales; Lennart Hammarström; Shigeaki Nonoyama; Isabella Quinti; John M Routes; Mimi L K Tang; Klaus Warnatz
Journal:  J Allergy Clin Immunol Pract       Date:  2015-11-07

2.  T and B lymphocyte subpopulations and activation/differentiation markers in patients with selective IgA deficiency.

Authors:  J Litzman; M Vlková; Z Pikulová; D Stikarovská; J Lokaj
Journal:  Clin Exp Immunol       Date:  2007-02       Impact factor: 4.330

3.  Age dependency and mutual relations in T and B lymphocyte abnormalities in common variable immunodeficiency patients.

Authors:  M Vlková; V Thon; M Sárfyová; L Bláha; A Svobodník; J Lokaj; J Litzman
Journal:  Clin Exp Immunol       Date:  2006-02       Impact factor: 4.330

4.  Thymic and bone marrow output in patients with common variable immunodeficiency.

Authors:  Federico Serana; Paolo Airò; Marco Chiarini; Cinzia Zanotti; Mirko Scarsi; Micol Frassi; Vassilios Lougaris; Alessandro Plebani; Luigi Caimi; Luisa Imberti
Journal:  J Clin Immunol       Date:  2011-04-14       Impact factor: 8.317

5.  B-cell and T-cell phenotypes in CVID patients correlate with the clinical phenotype of the disease.

Authors:  Gaël Mouillot; Maryvonnick Carmagnat; Laurence Gérard; Jean-Luc Garnier; Claire Fieschi; Nicolas Vince; Lionel Karlin; Jean-François Viallard; Roland Jaussaud; Julien Boileau; Jean Donadieu; Martine Gardembas; Nicolas Schleinitz; Felipe Suarez; Eric Hachulla; Karen Delavigne; Martine Morisset; Serge Jacquot; Nicolas Just; Lionel Galicier; Dominique Charron; Patrice Debré; Eric Oksenhendler; Claire Rabian
Journal:  J Clin Immunol       Date:  2010-05-01       Impact factor: 8.317

6.  Myeloid glycosylation defects lead to a spontaneous common variable immunodeficiency-like condition with associated hemolytic anemia and antilymphocyte autoimmunity.

Authors:  Sean O Ryan; Derek W Abbott; Brian A Cobb
Journal:  J Immunol       Date:  2014-05-02       Impact factor: 5.422

7.  Common variable immunodeficiency-associated endotoxemia promotes early commitment to the T follicular lineage.

Authors:  Carole Le Coz; Bertram Bengsch; Caroline Khanna; Melissa Trofa; Takuya Ohtani; Brian E Nolan; Sarah E Henrickson; Michele P Lambert; Taylor Olmsted Kim; Jenny M Despotovic; Scott Feldman; Olajumoke O Fadugba; Patricia Takach; Melanie Ruffner; Soma Jyonouchi; Jennifer Heimall; Kathleen E Sullivan; E John Wherry; Neil Romberg
Journal:  J Allergy Clin Immunol       Date:  2019-08-22       Impact factor: 10.793

8.  Deficiency of somatic hypermutation of immunoglobulin G transcripts is a better predictor of severe respiratory tract infections than lack of memory B cells in common variable immunodeficiency.

Authors:  Lone Schejbel; Hanne Marquart; Vagn Andersen; Henrik Permin; Pernille Andersen; Arne Svejgaard; Torben Barington
Journal:  J Clin Immunol       Date:  2005-07       Impact factor: 8.317

9.  Chronic immune activation in common variable immunodeficiency (CVID) is associated with elevated serum levels of soluble CD14 and CD25 but not endotoxaemia.

Authors:  J Litzman; J Nechvatalova; J Xu; O Ticha; M Vlkova; Z Hel
Journal:  Clin Exp Immunol       Date:  2012-12       Impact factor: 4.330

10.  Serum bactericidal activity against Helicobacter pylori in patients with hypogammaglobulinaemia.

Authors:  I M E Desar; M van Deuren; T Sprong; J B M J Jansen; F Namavar; C M Vandenbroucke-Grauls; J W M van der Meer
Journal:  Clin Exp Immunol       Date:  2009-06       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.